臨床婦人科産科67巻8号

2013年08月発行

今月の臨床 婦人科がんの予防戦略と早期診断 子宮頸がん

4．新たなHPVワクチンの開発

著者： 川名敬¹

所属機関： ¹東京大学大学院医学系研究科産科婦人科学講座

ページ範囲：P.790 - P.797

●子宮頸がんの予防効果を高めるための次世代のHPVワクチンの開発が進んでいる．

●HPVを標的にした細胞性免疫を誘導する免疫療法が期待される．

●CIN2～3に対する治療薬としてE7標的がんワクチンを開発中である．

参考文献

1） Koutsky LA, Ault KA, Wheeler CM, et al : A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 : 1645─1651, 2002

2） Villa LL, Costa RL, Petta CA, et al : High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 : 1459─1466, 2006

3） Muñoz N, Manalastas R Jr, Pitisuttithum P, et al : Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus（types 6, 11, 16, 18） recombinant vaccine in women aged 24-45 years : a randomised, double-blind trial. Lancet 373 : 1949─1957, 2009

4） Paavonen J, Naud P, Salmerón J, et al : Efficacy of human papillomavirus（HPV）-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types（PATRICIA） : final analysis of a double-blind, randomised study in young women. Lancet 374 : 301─314, 2009

5） Brown DR, Kjaer SK, Sigurdsson K, et al : The Impact of Quadrivalent Human Papillomavirus（HPV ; Types 6, 11, 16, and 18） L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years, J Infect Dis 199 : 926─935, 2009

6） Miura S, Matsumoto K, Oki A, et al : Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer 119 : 2713─2715, 2006

7） ACIP, Gardasil Briefing Information, ACIP Website, CDC

8） Olsson SE, Kjaer SK, Sigurdsson K, et al : Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccine 5 : 696─704, 2009

9） Kawana K, Yoshikawa H, Taketani Y, et al : In vitro construction of pseudovirions of human papillomavirus type 16 : incorporation of plasmid DNA into reassembled L1/L2 capsids. J Virol 72 : 10298─10300, 1998

10） Kawana K, Matsumoto K, Yoshikawa H, et al : A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2. Virology 245 : 353─359, 1998

11） Kanda T, Kondo K : Development of an HPV vaccine for a broad spectrum of high-risk types. Hum Vaccine 5 : 43─45, 2009

12） Alphs HH, Gambhira R, Karanam B, et al : Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Pro Natl Acad Sci USA 105 : 5850─5855, 2008

13） Jagu S, Kwak K, Schiller JT, et al : Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol 87 : 6127─6136, 2013

14） Tumban E, Peabody J, Tyler M, et al : VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS One 7 : e49751, 2012

15） Broad Spectrum HPV Vaccine Study（V503-001）in 16-to 26-Year-Old Women, Clinical Trials. Gov, U.S. National Institutes of Health, http://clinicaltrials.gov/ct2/show/study/NCT00543543?term=HPV+V503&rank=1&show_locs=Y#locn

16） Nakagawa M, Stites DP, Farhat S, et al : Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16 : Relationship to cervical intraepithelial neoplasia. J Infect Dis 175 : 927, 1997

17） Ressler S, Scheiden R, Dreier K, et al : High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma. Clin Cancer Res 13 : 7067─7072, 2007

18） Kojima S, Kawana K, Fujii T, et al : Characterization of intraepithelial lymphocytes（IELs） residing in the cervical mucosa of patients with human papillomavirus（HPV）-infected intraepithelial neoplastic lesions. Am J Reprod Immunol 66 : 435─443, 2011

19） Adachi K, Kawana K, Yokoyama T, et al : Oral immunization with Lactobacillus casei vaccine expressing human papillomavirus（HPV） type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocyte against HPV16 E7. Vaccine 28 : 2810─2817, 2010